Amarantus Biosci Inc (AMBS) 0.0730 $AMBS
Amarantus Acquires Additional Rights to LymPro Test From Memory Dx
GlobeNewswire - Mon May 05, 1:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that it has acquired additional rights for its flagship Alzheimer's blood diagnostic LymPro Test (R) from Memory Dx, LLC. The rights acquired by Amarantus are related to certain improvements that were sought out for the LymPro assay following the completion of work published in 2012 in the scientific journal Neurobiology of Aging. Memory Dx and Amarantus identified that these data sets fall outside the purview of Memory Dx' license agreement with the University of Leipzig, thereby allowing Memory Dx to sell the rights outright to Amarantus, without related milestones and royalties.
Amarantus Announces Positive Independent Peer-Reviewed Preclinical Data for MANF in Alzheimer's and Diabetes
GlobeNewswire - Thu May 01, 10:46AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the publication of positive independent peer-reviewed data on MANF in the areas of Alzheimer's disease and Diabetes, as well as additional studies further supporting its critical role in proper cellular function. The studies further corroborate the role of MANF's critical importance in reducing misfolded protein concentration and improving proper overall endoplasmic reticulum function.
Amarantus CSO to Present on PhenoGuard Data at Astrocytes in Health and Neurodegenerative Disease in London
GlobeNewswire - Mon Apr 28, 7:43AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that Co-Founder and Chief Scientific Officer John W. Commissiong, PhD will present preliminary data on PhenoGuard, the Company's proprietary neurotrophic growth factor discovery platform that yielded the discovery of MANF, at the "Astrocytes in Health and Neurodegenerative Disease: A joint Biochemical Society/British Neuroscience Association Focused Meeting" conference in London, England.
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqkpbq/retinitis) has announced the addition of the "Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics Drug Profiles - unoprostone isopropyl - NT-501 - Recombinant Human Nerve Growth Factor - valproic acid - UshStat - QLT-091001 - rAAV2-VMD2-hMERTK - Gene Therapy for Retinitis Pigmentosa and Glaucoma - Mesenchymal Stem Cell - emixustat hydrochloride - BDM-E - AMRS-001 - ReN-003 - Gene Therapy To Activate RPGR For X-Linked Retinitis Pigmentosa - RST-001 - Cyclic Nucleotide Analogue - GT-038 - Retinal Pigment Epithelial Progenitor Cells for Ophthalmology - Gene Therapy For Ophthalmology - proinsulin human SR - PRO-015 - Small Molecule for Retinitis Pigmentosa - FIB-111 - Compound-9 - Optogenetic Therapy for Retinitis Pigmentosa - norgestrel - CB-11 - Drug for Retinitis Pigmentosa - BNP-RP - Small Molecules for CNS Disorders and Ophthalmology - Small Molecule To Agonize Neurotrophin Receptor For Retinitis Pigmentosa - tetracaine - Compound-5 - Small Molecules Targeting Nuclear Receptors for Retinitis Pigmentosa - Gene Therapy For Ocular Diseases - Stem Cell Derived Three-Dimensional (3D) Retinal Tissue for Ophthalmology - Stem Cell Therapy for Retinitis Pigmentosa Companies Mentioned: - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/xqkpbq/retinitis
Amarantus Announces 2013 Year End Financial Results
GlobeNewswire - Mon Apr 21, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today reported financial results and developmental progress for the year ended December 31, 2013.
Amarantus elects Dr Charlotte Keywood as CMO of therapeutics division
M2 - Tue Apr 08, 6:37AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) disclosed on Tuesday ththat it has appointed Dr Charlotte Keywood, MD, as chief medical officer of its therapeutics division.
Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
GlobeNewswire - Tue Apr 08, 5:12AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the appointment of Charlotte Keywood, MD, as Chief Medical Officer of the Company's therapeutics division. Dr. Keywood brings over 20 years of experience in the biopharmaceutical drug development industry, including the development of Parkinson's disease Levadopa-Induced Dyskynesia (PD LID) drug candidates.
Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
GlobeNewswire - Tue Apr 01, 5:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the appointment of Mr. Robert Farrell, J.D. as Chief Financial Officer. Mr. Farrell brings over 20 years of healthcare, public company and CFO experience to Amarantus. Mr. Marc Faerber will continue with Amarantus in his new role as Corporate Controller and Vice President of Financial Operations.
Amarantus Bioscience Holdings, Inc. - "Commercialization On-Track for 2014: Updating LymPro Test(R) Progress"
ACCESSWIRE - Mon Mar 31, 10:40AM CDT
SAN FRANCISCO, CA / March 31, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Appoints Dr. Louis Kirby to Board of Advisors
GlobeNewswire - Mon Mar 31, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today appointed Dr. Louis Kirby to the Board of Advisors to assist the Company in the development and commercialization of the LymPro Test(R) for Alzheimer's disease. Dr. Kirby is a Board certified neurologist who brings over 25 years of industry experience to Amarantus, including work as principal investigator on nearly 400 clinical trials, including drug and diagnostic trials in Alzheimer's disease and other neurodegenerative conditions.
Cavendish Selects Amarantus to Present at the Cavendish Global Health Impact Forum
GlobeNewswire - Wed Mar 26, 7:01AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, announced today that it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 in New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and the private-sector engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
Amarantus BioScience Holdings, Inc. "Transformational Funding Positions Amarantus Heading into 2014 Milestones"
ACCESSWIRE - Mon Mar 10, 12:46PM CDT
New York, NY / ACCESSWIRE / March 10, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Mar 10, 5:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTC:AMBS) (Amarantus or the Company), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced today that it has closed on its previously announced Warrant Solicitation, which the Company elected to increase in size from $3.0M to $3.6M due to oversubscriptions. Concurrently, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"
, a Chicago-based institutional investor. LPC initially purchased 4.0 million shares of Amarantus' common stock at $0.10 per share for $400,000 and has committed to invest, at the sole option of Amarantus, up to an additional $19.6M of equity capital over the term of the purchase agreement. The total gross proceeds to the Company from these two transactions upon closing is $4M.
Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
GlobeNewswire - Thu Mar 06, 6:24AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it entered into an exclusive option agreement with the University of Massachusetts to license the University's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of antibiotic-induced ototoxicity. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for antibiotic-induced ototoxicity and certain other disorders of the ear. The Company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.
Amarantus Outlines MANF Research Collaboration Strategy
GlobeNewswire - Mon Mar 03, 11:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today outlined its research collaboration strategy for MANF, the Company's flagship therapeutic protein candidate. Concurrently, the Company expanded the list of select scientific publications for MANF on its website to forty two and highlighted key abstracts focusing on the therapeutic potential for MANF in retinal degeneration from the University of Miami's Bascom Palmer Eye Institute and a new abstract from researchers at the Buck Institute on Aging. A link to this updated scientific MANF information can be found at: http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus BioScience Holdings, Inc. "Q1-2014: The Maturation of Amarantus"
ACCESSWIRE - Mon Feb 24, 10:10AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
M2 - Mon Feb 24, 7:54AM CST
February 24, 2014 / M2 PRESSWIRE / BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTCBB: AMBS) after releasing the latest short sale data through February 21, 2014. The total aggregate number of shares shorted since June 2011 is approximately 902 million shares. Approximately 29.92% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.06. A short squeeze has begun as AMBS is above its SqueezeTrigger Price.
Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs
GlobeNewswire - Mon Feb 24, 6:12AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has appointed Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs. Mr. Segal will be responsible for in-licensing and out-licensing activities, as well as merger and acquisition opportunities across therapeutics and diagnostics areas. Ms. Clark will be responsible for overseeing all regulatory activities, including support of business development activities.
CEO Gerald Commissiong of Amarantus to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Feb 19, 6:15AM CST
Amarantus Bioscience Holdings, Inc. (OTCBB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network.
Amarantus Acquires Additional Rights to LymPro Test From Memory Dx
GlobeNewswire - Mon May 05, 1:00PM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that it has acquired additional rights for its flagship Alzheimer's blood diagnostic LymPro Test (R) from Memory Dx, LLC. The rights acquired by Amarantus are related to certain improvements that were sought out for the LymPro assay following the completion of work published in 2012 in the scientific journal Neurobiology of Aging. Memory Dx and Amarantus identified that these data sets fall outside the purview of Memory Dx' license agreement with the University of Leipzig, thereby allowing Memory Dx to sell the rights outright to Amarantus, without related milestones and royalties.
Amarantus Announces Positive Independent Peer-Reviewed Preclinical Data for MANF in Alzheimer's and Diabetes
GlobeNewswire - Thu May 01, 10:46AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the publication of positive independent peer-reviewed data on MANF in the areas of Alzheimer's disease and Diabetes, as well as additional studies further supporting its critical role in proper cellular function. The studies further corroborate the role of MANF's critical importance in reducing misfolded protein concentration and improving proper overall endoplasmic reticulum function.
Amarantus CSO to Present on PhenoGuard Data at Astrocytes in Health and Neurodegenerative Disease in London
GlobeNewswire - Mon Apr 28, 7:43AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced that Co-Founder and Chief Scientific Officer John W. Commissiong, PhD will present preliminary data on PhenoGuard, the Company's proprietary neurotrophic growth factor discovery platform that yielded the discovery of MANF, at the "Astrocytes in Health and Neurodegenerative Disease: A joint Biochemical Society/British Neuroscience Association Focused Meeting" conference in London, England.
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqkpbq/retinitis) has announced the addition of the "Global Retinitis Pigmentosa (Retinitis) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics Drug Profiles - unoprostone isopropyl - NT-501 - Recombinant Human Nerve Growth Factor - valproic acid - UshStat - QLT-091001 - rAAV2-VMD2-hMERTK - Gene Therapy for Retinitis Pigmentosa and Glaucoma - Mesenchymal Stem Cell - emixustat hydrochloride - BDM-E - AMRS-001 - ReN-003 - Gene Therapy To Activate RPGR For X-Linked Retinitis Pigmentosa - RST-001 - Cyclic Nucleotide Analogue - GT-038 - Retinal Pigment Epithelial Progenitor Cells for Ophthalmology - Gene Therapy For Ophthalmology - proinsulin human SR - PRO-015 - Small Molecule for Retinitis Pigmentosa - FIB-111 - Compound-9 - Optogenetic Therapy for Retinitis Pigmentosa - norgestrel - CB-11 - Drug for Retinitis Pigmentosa - BNP-RP - Small Molecules for CNS Disorders and Ophthalmology - Small Molecule To Agonize Neurotrophin Receptor For Retinitis Pigmentosa - tetracaine - Compound-5 - Small Molecules Targeting Nuclear Receptors for Retinitis Pigmentosa - Gene Therapy For Ocular Diseases - Stem Cell Derived Three-Dimensional (3D) Retinal Tissue for Ophthalmology - Stem Cell Therapy for Retinitis Pigmentosa Companies Mentioned: - QLT Inc. - Sanofi - Sun Pharmaceutical Industries Limited - BioDiem Ltd - ReGenX Biosciences, LLC - ReNeuron Group plc - R-Tech Ueno, Ltd. - Acucela Inc. - Neurotech Pharmaceuticals, Inc. - Orphagen Pharmaceuticals, Inc. - Grupo Ferrer Internacional, S.A. - Stemedica Cell Technologies, Inc. - Asklepios BioPharmaceutical, Inc. - to-BBB technologies BV - Dompe Farmaceutici S.p.A. - DNAVEC Corporation - Bikam Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Genable Technologies Limited - California Stem Cell, Inc. - Amarantus Bioscience Holdings, Inc. - GenSight Biologics For more information visit http://www.researchandmarkets.com/research/xqkpbq/retinitis
Amarantus Announces 2013 Year End Financial Results
GlobeNewswire - Mon Apr 21, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today reported financial results and developmental progress for the year ended December 31, 2013.
Amarantus elects Dr Charlotte Keywood as CMO of therapeutics division
M2 - Tue Apr 08, 6:37AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) disclosed on Tuesday ththat it has appointed Dr Charlotte Keywood, MD, as chief medical officer of its therapeutics division.
Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
GlobeNewswire - Tue Apr 08, 5:12AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the appointment of Charlotte Keywood, MD, as Chief Medical Officer of the Company's therapeutics division. Dr. Keywood brings over 20 years of experience in the biopharmaceutical drug development industry, including the development of Parkinson's disease Levadopa-Induced Dyskynesia (PD LID) drug candidates.
Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
GlobeNewswire - Tue Apr 01, 5:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the appointment of Mr. Robert Farrell, J.D. as Chief Financial Officer. Mr. Farrell brings over 20 years of healthcare, public company and CFO experience to Amarantus. Mr. Marc Faerber will continue with Amarantus in his new role as Corporate Controller and Vice President of Financial Operations.
Amarantus Bioscience Holdings, Inc. - "Commercialization On-Track for 2014: Updating LymPro Test(R) Progress"
ACCESSWIRE - Mon Mar 31, 10:40AM CDT
SAN FRANCISCO, CA / March 31, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Appoints Dr. Louis Kirby to Board of Advisors
GlobeNewswire - Mon Mar 31, 7:30AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today appointed Dr. Louis Kirby to the Board of Advisors to assist the Company in the development and commercialization of the LymPro Test(R) for Alzheimer's disease. Dr. Kirby is a Board certified neurologist who brings over 25 years of industry experience to Amarantus, including work as principal investigator on nearly 400 clinical trials, including drug and diagnostic trials in Alzheimer's disease and other neurodegenerative conditions.
Cavendish Selects Amarantus to Present at the Cavendish Global Health Impact Forum
GlobeNewswire - Wed Mar 26, 7:01AM CDT
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, announced today that it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 in New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and the private-sector engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
Amarantus BioScience Holdings, Inc. "Transformational Funding Positions Amarantus Heading into 2014 Milestones"
ACCESSWIRE - Mon Mar 10, 12:46PM CDT
New York, NY / ACCESSWIRE / March 10, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus Closes Warrant Solicitation; Enters Into $20 Million Purchase Agreement With Lincoln Park Capital Fund, LLC
GlobeNewswire - Mon Mar 10, 5:00AM CDT
Amarantus Bioscience Holdings, Inc. (OTC:AMBS) (Amarantus or the Company), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced today that it has closed on its previously announced Warrant Solicitation, which the Company elected to increase in size from $3.0M to $3.6M due to oversubscriptions. Concurrently, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"
, a Chicago-based institutional investor. LPC initially purchased 4.0 million shares of Amarantus' common stock at $0.10 per share for $400,000 and has committed to invest, at the sole option of Amarantus, up to an additional $19.6M of equity capital over the term of the purchase agreement. The total gross proceeds to the Company from these two transactions upon closing is $4M. Amarantus Acquires Exclusive Option to License Intellectual Property for Use of MANF and CDNF to Treat Antibiotic-Induced Ototoxicity
GlobeNewswire - Thu Mar 06, 6:24AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it entered into an exclusive option agreement with the University of Massachusetts to license the University's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of antibiotic-induced ototoxicity. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for antibiotic-induced ototoxicity and certain other disorders of the ear. The Company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.
Amarantus Outlines MANF Research Collaboration Strategy
GlobeNewswire - Mon Mar 03, 11:00AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today outlined its research collaboration strategy for MANF, the Company's flagship therapeutic protein candidate. Concurrently, the Company expanded the list of select scientific publications for MANF on its website to forty two and highlighted key abstracts focusing on the therapeutic potential for MANF in retinal degeneration from the University of Miami's Bascom Palmer Eye Institute and a new abstract from researchers at the Buck Institute on Aging. A link to this updated scientific MANF information can be found at: http://ir.stockpr.com/amarantus/scientific-publications.
Amarantus BioScience Holdings, Inc. "Q1-2014: The Maturation of Amarantus"
ACCESSWIRE - Mon Feb 24, 10:10AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) published a new blog post on The Chairman's Blog, written by the company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
M2 - Mon Feb 24, 7:54AM CST
February 24, 2014 / M2 PRESSWIRE / BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTCBB: AMBS) after releasing the latest short sale data through February 21, 2014. The total aggregate number of shares shorted since June 2011 is approximately 902 million shares. Approximately 29.92% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.06. A short squeeze has begun as AMBS is above its SqueezeTrigger Price.
Amarantus Strengthens Management Team With Key Additions in Business Development and Regulatory Affairs
GlobeNewswire - Mon Feb 24, 6:12AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has appointed Kerry Segal as Head of Business Development and Tiffini Clark as Head of Regulatory Affairs. Mr. Segal will be responsible for in-licensing and out-licensing activities, as well as merger and acquisition opportunities across therapeutics and diagnostics areas. Ms. Clark will be responsible for overseeing all regulatory activities, including support of business development activities.
CEO Gerald Commissiong of Amarantus to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Wed Feb 19, 6:15AM CST
Amarantus Bioscience Holdings, Inc. (OTCBB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network.
